ChronicComplement Activation in Aging Retina Reflects a Breakdown in Mitochondrial‑Danger Signaling Resolution, Not a Hormetic Adaptation

Hypothesis

Chronic complement activation in the aging retina is not a maladaptive hormetic response but a failure to resolve mitochondrial danger signaling, leading to sustained C3 production and inflammasome activation.

Mechanistic Basis

In young retinal pigment epithelium (RPE), low-level complement activation aids photoreceptor outer segment clearance and induces protective heat shock proteins via FHL‑1 binding [1]. This transient response depends on efficient mitochondrial turnover and rapid clearance of oxidative damage. With age, accumulation of bisretinoids such as A2E impairs lysosomal function, causing mitochondrial damage and release of mitochondrial DNA (mtDNA) into the cytosol [3]

We believe that mtDNA activates the cGAS‑STING pathway, which drives NF‑κB–dependent transcription of C3 and other complement components, creating a feed‑forward loop that overwhelms endogenous regulators like CFH. Simultaneously, age‑related decline in NAD+ reduces SIRT1 activity, diminishing deacetylation and stabilization of complement inhibitors, further tipping the balance toward persistence [2]

Thus, what appears as overactivation is actually a chronic danger signal that the cell cannot shut off because the upstream mitochondrial stress remains unresolved.

Testable Predictions

1. In aged RPE, cytosolic mtDNA levels will correlate with C3 deposition and will be higher than in young tissue.
2. Pharmacological inhibition of cGAS (e.g., with RU.521) or STING (e.g., with C-176) will reduce C3 mRNA and protein levels in aged RPE cultures without affecting basal complement activity needed for housekeeping.
3. Restoring NAD+ (e.g., with NR supplementation) will enhance SIRT1‑mediated deacetylation of CFH, increasing its regulatory capacity and lowering MAC formation in aged retina.
4. Double manipulation—mtDNA depletion (via mitoTALENs) plus NAD+ boosting—will synergistically prevent drusen‑like deposits in a mouse model of aging.

Potential Experiments

• Isolate cytosolic fractions from young and old mouse RPE, quantify mtDNA by qPCR, and complement C3 by ELISA; assess correlation.
• Treat aged RPE cell lines with A2E to induce stress, then add cGAS/STING inhibitors; measure C3 transcription (RT‑qPCR) and secretion (ELISA).
• Use SIRT1 activators or NAD+ precursors in aged mice; assess CFH acetylation status (immunoprecipitation with acetyl‑lysine antibody) and complement activity (hemolytic assay).
• In Abca4‑/- mice (model of A2E accumulation), combine mitoTALEN‑mediated mtDNA reduction with nicotinamide riboside supplementation; evaluate drusen volume by OCT and histology.

Implications

If chronic complement activation stems from unresolved mitochondrial danger signaling, therapeutic strategies should target the source of the signal rather than bluntly inhibiting complement. This reframes the hormesis concept: beneficial low‑level stress works because it activates resolvable danger pathways; aging pathology emerges when those pathways become stuck in the "on" position due to accumulated, non‑resolvable damage. Testing this hypothesis will clarify whether complement modulation alone is sufficient or whether upstream mitochondrial quality control is required for retinal health in aging.